HRMY Earnings Prediction
The chart below shows how HRMY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HRMY sees a -0.77% change in stock price 10 days leading up to the earnings, and a -1.64% change 10 days following the report. On the earnings day itself, the stock moves by +5.22%. This data can give you a slight idea of what to expect for the next quarter's release.
HRMY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
186.04M
16.08%
7.65%
Gross Margin
77.01%
-3.56%
-5.39%
Operating Margin
33.17%
-17.59%
49.08%
Net Margin
24.78%
3.25%
269.30%
EPS
0.79
25.40%
295.00%
No Data Available
HRMY Earnings Analysis
Harmony Biosciences Holdings, Inc. Common Stock Corporation (HRMY.O) Earnings Conference Call
Positive
Cumulative Net Sales Achievement: WAKIX generated net revenue of $186 million in Q3 2024, surpassing $2 billion in cumulative net sales since launch.
Operating Expenses Increase: Harmony reported a 29% increase in operating expenses to $81.6 million compared to $63.5 million in the same quarter last year, driven by investments in expanding late-stage pipeline programs.
Adjusted Net Income Growth: Non-GAAP adjusted net income for Q3 2024 was $59.6 million, or $1.03 per diluted share, compared to $58.8 million, or $0.97 per diluted share in the prior year quarter, reflecting strong underlying business performance.
Patient Base Growth: The average number of patients on WAKIX increased to approximately 6,800 in Q3 2024, contributing to continued growth in the adult narcolepsy patient base.
Financial Flexibility for Growth: The company ended Q3 2024 with $504.7 million in cash, cash equivalents, and investments, providing financial flexibility to execute on growth opportunities.
Negative
Net Sales Decline: Net sales for the third quarter were $186 million, compared to $160.3 million in the prior year quarter, indicating a decline in year-over-year growth.
Operating Expenses Increase: Total operating expenses for the third quarter were $81.6 million, compared to $63.5 million for the same quarter in 2023, representing a 29% increase.
Adjusted Net Income Growth: Non-GAAP adjusted net income for the third quarter of 2024 was $59.6 million or $1.03 per diluted share compared to $58.8 million or $0.97 per diluted share in the prior year quarter, showing minimal growth.
Liquidity Decrease Analysis: The company ended the third quarter with $504.7 million of cash, cash equivalents, and investments, reflecting a decrease in liquidity compared to previous quarters.
2024 Revenue Guidance Challenges: The guidance for 2024 net revenue was reiterated at $700 million to $720 million, indicating potential challenges in achieving higher revenue growth.
HRMY FAQs
How does HRMY typically perform around its earnings report dates?
Is Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HRMY Earning Call Sentiment
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
HRMY.O
0%Positive
The earnings call highlights strong financial performance with a 16% revenue increase and stable net income, despite rising expenses. The FDA approval for pediatric narcolepsy and the $1 billion market potential for WAKIX are promising. The Q&A indicates confidence in product differentiation and market strategy. The company's robust cash position supports pipeline growth, although competitive and regulatory risks exist. The reiterated guidance and potential peak sales for Pitolisant suggest positive sentiment. Given the mid-sized market cap, the stock is likely to experience a positive reaction.
